About our platform

Our investigational medical device delivers non-invasive neuromodulation with the potential to improve outcomes in a range of neurodegenerative diseases, including Alzheimer’s disease, and is personalized based on your brain’s responses.

The platform

Intuitive experience for at-home patient self-administration.

Features:

Personalized treatments

Adjustable fit

Self-administered

Platform
Mechanism of Action

Cognito uses sensory stimulation to evoke gamma oscillations in the brain that have 
been shown to improve synaptic connections between neurons, activate microglia, and enhance removal of pathological proteins 
from the brain.

This leads to reduced neurodegeneration 
and brain atrophy, as well as improved sleep, cognitive and functional abilities.

Our Pipeline

Leveraging our platform across multiple neurodegenerative diseases

Focus

CogTx-001

Alzheimer's Disease

CogTx-002

Mild Cognitive Impairment

CogTx-003

Parkinson's Disease

CogTx-004

TBI-related Dementia

CogTx-005

Ischemic Stroke

CogTx-006

Multiple Sclerosis

Discovery

Preclinical

Early Clinical

Pivotal Clinical

In market